Treatment of schizophrenia: Discussion

    Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

    Abstract

    Rajiv Tandon reminds us that since chlorpromazine, no less than 60 antipsychotic drugs have been marketed. Clozapine proved a milestone in treatment effectiveness for patients with schizophrenia. The subsequently developed atypical antipsychotic drugs, now known as second-generation antipsychotics (SGAs), were heralded as the first major advance in the therapeutics of schizophrenia for 40 years. These drugs seemed to have important advantages over first-generation (FGA; typical or conventional) drugs, including better efficacy for positive, negative, and mood symptoms, with fewer adverse effects and the possibility of improving cognition. It was claimed that the increased cost of the newer drugs would be offset by savings resulting from decreased hospital stays and use of health-care services.
    Original languageUndefined
    Title of host publicationAdvances in Schizophrenia Research 2009
    EditorsWagner F. Gattaz, Geraldo Busatto
    PublisherSpringer Nature
    Pages441-445
    Number of pages5
    ISBN (Electronic)978-1-4419-0913-8
    ISBN (Print)978-1-4899-8321-3
    DOIs
    Publication statusE-pub ahead of print - 5 Sept 2009

    Keywords

    • Antipsychotic drug
    • Atypical antipsychotic drug
    • Decrease hospital stay

    Cite this